INTRODUCTION:

Metabolic syndrome (MetS) is a complex condition that has become a major global health issue and a significantsocioeconomic burden on worldwide populations. Because of the combination of several interconnected metabolicabnormalities, MetS is frequently referred to as a syndrome. It raises the risk of a variety of serious illnesses, particularly among them coronary heart disease (CHD, other types of cardiovascular atherosclerotic diseases (CVD), and type 2 diabetes mellitus (T2DM)^24,21.

Instead of being a single illness in and of itself, the syndrome is a collection of metabolic abnormalities that increase a person's risk of developing various chronic and possibly fatal conditions. A group of linked metabolic disorders known as metabolic syndrome considerably raises a person's risk of cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and all-cause death. Central obesity, insulin resistance, dyslipidemia, hypertension, and elevated fasting blood glucose levels are among the characteristics that diagnose it. Because the syndrome is becoming more common and is associated with poor nutrition and increasing obesity rates worldwide, it represents a risk to global health¹⁷. A collection of related metabolic risk factors form the metabolic syndrome. Dyslipidemia: This is characterized by decreased concentrations of high-density lipoproteins (HDL) and increased levels of triglycerides and lipoproteins containing ApoB in the bloodstream. Vascular disease and atherogenesis are accelerated by these irregularities abnormal in lipids¹⁸. Hypertension: A common and important component of the condition, elevated arterial blood pressure raises the risk of cardiovascular disease¹⁶. Dysregulated glucose homeostasis: This might present in the form of overt type 2 diabetes mellitus, insulin resistance (IR), or impaired fasting glucose. Obesity in the abdomen: Visceral or central adiposity is regarded as an important characteristic of metabolic syndrome and is intimately associated with inflammatory conditions and insulin resistance¹⁷.

HISTORY:

The idea of metabolic syndrome (MetS) has evolved over almost a century as people became more aware that various metabolic problems cluster together, raising the risk of type 2 diabetes and cardiovascular disease. Obesity, hypertension, and hyperglycemia were frequently seen in individuals with cardiovascular problems in the early 1900s, but these disorders were treated independently. Endocrinologist Gerald Reaven's 1988 proposal of "Syndrome X," which postulated that insulin resistance—the decreased sensitivity of cells to insulin—was the underlying mechanism connecting poor glucose tolerance, hypertension, dyslipidemia, and obesity, marked a significant turning point. As a result, medical knowledge changed from treating discrete illnesses to identifying a common pathogenesis. Insulin resistance, blood pressure, lipid levels, fasting glucose, and waist circumference were all included in the diagnostic criteria that were later developed by organizations such as WHO, NCEP ATP III, and IDF, along with ethnicity-specific thresholds. Despite these recommendations, there is still disagreement about whether MetS is a separate clinical entity or just a handy collection of risk factors, underscoring the need for more study to enhance diagnosis and treatment.^2,24

Types and Classification of Metabolic Syndrome (Mets):

Metabolic syndrome (MetS) is identified as a multifaceted clinical disorder comprising interrelated metabolic risk factors that notably elevate the likelihood of cardiovascular disease, type 2 diabetes, and other long-term complications. While diagnosis relies on specific criteria like waist circumference, blood pressure, fasting glucose, triglycerides, and HDL cholesterol, people may exhibit different underlying mechanisms. Grasping these differences offers greater insight into the syndrome's variety and aids in developing more precise management strategies. A key subtype is the mainly insulin-resistant type, where insulin resistance acts as the main pathophysiological mechanism. Under this condition, the body's cells do not adequately respond to insulin, leading the pancreas to produce more insulin, thus causing compensatory hyperinsulinemia. People with this subtype frequently exhibit markedly higher fasting insulin levels while glucose stays normal, occasionally for several years prior to the onset of diabetes. This phenotype is closely associated with visceral fat, which is metabolically active and releases inflammatory cytokines like TNF-α and IL-6. These elements exacerbate insulin resistance, initiate systemic inflammation, and lead to dyslipidemia marked by elevated triglycerides, reduced HDL cholesterol, and small dense LDL particles²⁴. Insulin resistance additionally encourages hypertension by causing renal sodium retention and activating the sympathetic nervous system. Management aims to enhance insulin sensitivity via weight reduction, dietary modifications, increased physical activity, and medications like metformin or thiazolidinediones. A significant subtype is the obesity-focused type, where central abdominal fat is the main cause of metabolic issues. People exhibit greater waist circumference and considerable visceral fat buildup, which interferes with liver metabolism by releasing free fatty acids into portal circulation. This results in increased hepatic glucose production, dyslipidemia, and worsening insulin resistance. Inflammatory substances from fat tissue also hinder endothelial function and encourage hypertension. Individuals with this subtype frequently display elevated triglycerides, reduced HDL cholesterol, and high blood pressure, with Insulin resistance, dyslipidemia, hypertension, and elevated cardiovascular risk are all closely linked to obesity³¹. Therapeutic approaches focus on reducing weight via calorie management, consistent physical activity, behavioral changes, and pharmacological treatments for obesity like GLP-1 receptor agonists. In extreme situations, bariatric surgery might be an option. A third subtype is the hypertensive variant, where high blood pressure is the primary and most significant abnormality. People might experience hypertension that does not respond to typical treatments, along with other metabolic issues like dyslipidemia or insulin resistance appearing as additional complications. Hypertension in this subtype is caused by various mechanisms such as sodium retention linked to hyperinsulinemia, stimulation of the renin-angiotensin-aldosterone system, excessive sympathetic activity, and inflammation of blood vessels. These elements lead to increased arterial stiffness and reduced vasodilation. Effective management necessitates the use of several antihypertensive medications when warranted, coupled with lifestyle changes like lower sodium consumption, enhanced physical exercise, and weight reduction. Tackling simultaneous lipid or glucose irregularities enhances results even more. Collectively, these subtypes emphasize the diverse characteristics of metabolic syndrome and the necessity for personalized treatment approaches tailored to specific underlying pathophysiological processes^16,25.

Symptoms of Metabolic Syndrome:

Metabolic syndrome (MetS) is frequently characterized as a “silent” disorder since it usually does not exhibit obvious symptoms during its initial phases. Rather, it is determined by clinical and laboratory evidence that uncovers a mix of metabolic risk factors. Identifying subtle indicators can aid in early detection and prompt treatment. A key characteristic is abdominal obesity, marked by an excess of fat around the midsection, which is metabolically active and closely associated with other elements of MetS. Hypertension is an important indicator often identified during regular health examinations, and while it seldom produces symptoms, it greatly heightens cardiovascular risk. Dyslipidemia, characterized by elevated triglycerides and reduced HDL cholesterol, often shows no symptoms but can be readily identified via blood tests. Diminished glucose control may remain undetected until hyperglycemia symptoms—like excessive thirst, frequent urination, fatigue, or blurred vision—manifest, particularly if type 2 diabetes arises. MetS is also linked to other ailments like non-alcoholic fatty liver disease (NAFLD), which can lead to liver swelling or pain in the upper right abdomen. A proinflammatory condition can cause nonspecific fatigue, and obstructive sleep apnea, prevalent among those with obesity, leads to disrupted sleep and daytime exhaustion. Since initial symptoms are few or nonexistent, consistent monitoring of blood pressure, waist size, blood glucose, and lipid levels is crucial to identify MetS promptly and avert serious complications like diabetes and cardiovascular disease^18.21.

Diagnosis of Metabolic Syndrome:

Metabolic syndrome is diagnosed by identifying a group of metabolic abnormalities that together raise a person's risk of developing cardiovascular disease and type 2 diabetes. Because metabolic syndrome consists of several risk factors rather than a single disease entity, no laboratory test or diagnostic method can clearly confirm its presence. Instead, diagnosis is based on established clinical criteria that consider crucial measurable characteristics such as body measures, blood pressure, and biochemical indicators. Several expert organizations have established diagnostic criteria, the most commonly utilized of which are from the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and the International Diabetes Federation (IDF)^1,2.

Metabolic Syndrome Complications:

Metabolic Syndrome (MetS) is a combination of connected metabolic disorders—including abdominal fat, insulin resistance, dyslipidemia, and high blood pressure—that greatly raise the likelihood of developing cardiovascular disease, type 2 diabetes (T2DM), and various other chronic ailments. These risk elements combine to create extensive and advancing issues that impact various organ systems. A significant result of MetS is T2DM, caused by insulin resistance and fatigue of pancreatic β-cells. Chronic hyperglycemia causes microvascular issues like diabetic retinopathy, nephropathy, and neuropathy, potentially leading to vision impairment, kidney failure, and amputations. Cardiovascular issues are the gravest consequences; dyslipidemia and hypertension hasten atherosclerosis, raising the risk of coronary artery disease, myocardial infarction, angina, as well as ischemic and hemorrhagic stroke. Peripheral artery disease additionally reduces blood circulation to the extremities and may result in tissue death. Renal issues develop as insulin resistance and hypertension harm glomerular blood vessels, leading to chronic kidney disease and possibly end-stage renal disease. Liver involvement, especially nonalcoholic fatty liver disease (NAFLD), can progress to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Neurological effects encompass cognitive deterioration, vascular dementia, and a heightened risk of Alzheimer’s because of inflammation and reduced cerebral blood circulation. MetS elevates the likelihood of surgical complications, such as increased postoperative mortality, wound dehiscence, infections at surgical sites, and cardiovascular events during the perioperative period. Patients frequently endure extended hospitalizations and increased rates of readmission. Other prolonged concerns include polycystic ovary syndrome (PCOS), obstructive sleep apnea, and higher vulnerability to specific cancers. Grasping these complications is crucial for prompt intervention and prevention in individuals with MetS. Obesity and hormonal dysregulation brought on by stress lead to insulin resistance, which in turn causes type 2 diabetes. One of the main endocrine complications of metabolic syndrome is this metabolic disruption. The risk of cardiovascular illnesses is greatly increased when obesity and prolonged stress are coupled. The main cardiovascular consequences of metabolic syndrome are endothelial dysfunction, hypertension, and atherosclerosis, all of which are exacerbated by stress-induced hormonal imbalance and elevated body mass index³³.

Pathophysiology of Metabolic Syndrome:

The complex condition referred to as Metabolic Syndrome (MetS) heightens the risk of type 2 diabetes, cardiovascular disease, and chronic illnesses due to interconnected metabolic and molecular irregularities. The causes include insulin resistance, central obesity, dyslipidemia, hypertension, pro-inflammatory states, and lifestyle choices. The primary issue is insulin resistance, leading to hyperinsulinemia and persistent hyperglycemia because the liver, muscle, and fat tissues cannot respond to insulin. Furthermore, this enhances the creation of triglycerides and disrupts insulin signaling by elevating lipolysis and free fatty acids¹⁷. Dysfunction of adipose tissue, particularly in visceral obesity, plays a major role. Enlarged fat cells secrete surplus inflammatory cytokines (TNF-α, IL-6, Resistin) and lower levels of adiponectin, promoting systemic inflammation, endothelial dysfunction, and abnormal fat accumulation in the liver, muscle, and pancreas, resulting in lipotoxicity and NAFLD. Mitochondrial overload elevates reactive oxygen species, leading to oxidative stress, hindered fatty-acid oxidation, and additional insulin resistance. MetS also includes atherogenic dyslipidemia, marked by elevated triglycerides, reduced HDL, and small dense LDL, which contribute to vascular injury and hypertension. Genetic and epigenetic influences, combined with HPA-axis overactivity and increased cortisol levels, encourage visceral fat storage and metabolic dysregulation. Furthermore, dysbiosis of gut microbiota elevates inflammation and modifies energy metabolism, further aiding in the progression of MetS^4,24. Phytopharmaceuticals and plant extracts have the ability to alter human metabolism in a way that avoids metabolic and chronic diseases³⁴.

NUTRACEUTICAL MANAGEMENT OF (METS)

1.Plant Proteins and Functional Foods in Metabolic Syndrome:

1.1 The Importance of Plant Proteins:

Higher total protein consumption appears to reduce the incidence of type 2 diabetes (T2D), and high-protein diets are frequently employed for weight reduction and maintenance. But the source of protein is important: -Consuming a lot of red meat is associated with an increased risk of T2D. -Plant proteins (lupin, soy, peas, wheat protein, etc.) are typically associated with improved lipid profiles, mild weight management, and a decreased risk of diabetes. Higher plant protein intake has been linked to a lower incidence of type 2 diabetes in large cohort data (e.g., Kuopio Ischemic Heart Disease Risk Factor Study). Lupin and soy proteins are particularly beneficial in smaller clinical studies for individuals with MetS; there is also modest support for wheat and pea proteins²⁰.

1.2 Lupin Proteins:

With a protein fraction high in 7S and 11S globulins (conglutins), lupin (Lupinus spp.) Is a legume high in protein and low in antinutritional factors. Important clinical findings in dyslipidemia and MetS increases the LDL:HDL ratio and lowers total and LDL cholesterol. Lupin protein concentrate decreased circulating PCSK9, a crucial regulator of LDL receptor (LDL-R) degradation, as well as LDL and non-HDL cholesterol in MetS. Anti-atherosclerotic and hypolipidemic benefits are demonstrated in animal models; TG lowering is more reliable in animals than in people. Action mechanism: 1. Modulation of PCSK9 and overexpression of LDL-R:- Lupin proteins improve the removal of LDL from plasma by activating LDL receptors in the liver. -LDL-R is further stabilized on the cell surface by a reduction in PCSK9 levels and modification of its interaction with LDL-R, maintaining cholesterol-lowering effects. 2. Support for insulin signaling and suppression of DPP-IV:-The enzyme dipeptidyl peptidase IV (DPP-IV), which breaks down incretins like GLP-1, is inhibited by peptides produced from lupin proteins, such as Lup1.-Conglutin B is a protein that may improve glycaemic management by modulating insulin signaling. -Safety and adverse consequences -Studies have shown that it is generally well tolerated; the primary risk is legume allergy (cross-reactivity with other pulses in some persons). -For those who are sensitive, excessive consumption may result in minor gastrointestinal (GI) discomfort (gas, bloating). Mechanism: Consumption of soy protein ⬇1. LDL-R Activation and Bile Acid Handling • Hepatic LDL-R expression ⬇ → LDL absorption by the liver → LDL-C circulation, fecal sterol excretion, and altered bile acid cycling A better lipid profile.2. Metabolic and hormonal modulation; insulin sensitivity; fasting glucose; improved body composition (fat mass, little weight reduction); isoflavones (modest estrogen-like actions); and support for lipid and vascular benefits (secondary function)Side effects: Studies have shown that it is generally well tolerated; the primary risk is legume allergy (cross-reactivity with other pulses in some persons).For those who are sensitive, excessive consumption may result in minor gastrointestinal (GI) discomfort (gas, bloating)^4,7.

1.3 Orthosiphon Stamineus:

Java tea, or Orthosiphon Stamineus, is a medicinal herb that has long been used to treat hypertension and diabetes. Hydro-alcoholic extracts of Orthosiphon Stamineus have been shown in experiments to have strong anti-inflammatory effects in models of acute and chronic inflammation, such as granuloma caused by cotton pellets and paw edema caused by carrageenan. Flavonoids and phenolic chemicals, which prevent the production and release of inflammatory mediators like prostaglandins, are primarily responsible for the reported anti-inflammatory benefits. These results imply that Orthosiphon Stamineus may be used as a supplemental herbal intervention to enhance metabolic and cardiovascular outcomes, given the key role of persistent low-grade inflammation in the pathophysiology of metabolic syndrome³².

2. Probiotics, Prebiotics, and Synbiotics: Modifying the Gut Microbiota:

Key elements of MetS, including energy harvesting, inflammation, insulin resistance, and lipid metabolism, are influenced by gut flora. MetS characteristics, T2D, and obesity are associated with dysbiosis (disturbed microbiota).

2.1 Bacteria:

When ingested in sufficient quantities, probiotics—live bacteria like Lactobacillus and Bifidobacterium—provide health advantages. Metabolic effects reported: When taken for at least eight weeks, overweight/obese people showed slight decreases in weight, BMI, and waist circumference.-Mild systolic and diastolic blood pressure drops, particularly when using more strains, larger dosages, and longer durations.-In those with T2D or increased baseline glucose, there is a little improvement in fasting plasma glucose.-While effects on HDL-C and TG are frequently negligible in the general dyslipidemic population, triglycerides may decrease in T2D. Mechanism: Supplementing with probiotics:1.Enhanced Gut Barrier → ■ Endotoxemia • Fortifies intestinal barrier → ■ LPS leaks into blood → ■ Systemic inflammation → ■ Resistance to insulin.2. The synthesis of SCFA (acetate, butyrate, and propionate), improved gut health and glucose metabolism, GLP-1 secretion, satiety, and insulin response are all beneficial metabolites and hormonal effects. Side effect: - Gas, bloating, and changes in bowel habits are mostly minor GI symptoms. -Use with caution in critically sick or immunocompromised individuals since they may be susceptible to rare but dangerous infections. -Many studies are small and diverse, and effects are strain-specific and not guaranteed²⁷.

2.2 Both Synbiotics and Prebiotics:

Synbiotics combine probiotics with prebiotics; prebiotics are non-digestible fibers (such as inulin, oligofructose, and GOS) that specifically encourage good bacteria.
Metabolic effects reported: Postprandial insulin and glucose responses have somewhat improved. -Prebiotics and synbiotics can cut fasting insulin and somewhat improve TG and HDL-C in those who are overweight or have diabetes. -Some studies show decreased appetite and increased satiety. Mechanism: 1. Selective fermentation leads to the production of Short-chain fatty acids (SCFAs); it is fermented by good gut microorganisms; it improves glucose and lipid metabolism; and it increases the release of gut hormones. 2. Modulation of Appetite Hormones: Ghrelin (hunger) PYY and GLP-1 (satiety hormones) Improved satiety Consumption of energy. Side Effect: Excessive dosages frequently result in gas, bloating, pain in the abdomen, and even diarrhea. -Although generally safe, dosage titration is necessary to reduce GI problems^3,21.

3. Metabolic Syndrome and Vitamin D:

In observational studies, the risk of MetS, T2D, obesity, and hypertension is negatively correlated with low serum 25(OH)D levels. Vitamin D levels are frequently reduced in obese people, presumably as a result of sequestration in adipose tissue. A decreased risk of MetS and T2D is linked to a higher vitamin D level. Reduced incident hypertension and marginally lower SBP and DBP are correlated with higher 25(OH)D levels. Supplementation studies, however, have mostly failed to demonstrate significant benefits on blood pressure, insulin resistance, fasting glucose, or HbA1c.Mechanism: 1. Impacts on insulin sensitivity and β-cell function: Peripheral tissues and pancreatic β-cells have vitamin D receptors; sufficient vitamin D may promote insulin production and β-cell survival.2. Renin-angiotensin-aldosterone system (RAAS) modification: By reducing RAAS activity, vitamin D may help reduce blood pressure and enhance vascular health. Side Effect: In general, physiological dosages (such as 600–2000 IU/day) are safe. Hypercalcemia, renal stone risk, and vascular calcification can result from extremely high or long-term intake. Patients taking high-dose medication or those with renal illness require monitoring^4,20.

4. Herbal and Polyphenolic Nutraceuticals for Metabolic Syndrome:

4.1 Curcuma Longa, or Curcumin:

The main polyphenol in turmeric is curcumin, which has potent anti-inflammatory and antioxidant properties as well as increasing evidence in MetS. Effects of metabolism: Enhances insulin sensitivity in prediabetes and MetS (lower HOMA-IR, better β-cell activity). -May stop prediabetes from developing into type 2 diabetes. -Lowers non-HDL-C and triglycerides while slightly raising HDL-C. -Enhances endothelial function and reduces inflammatory indicators, such as hs-CRP.- Curcuma inodora's dried methanol extract shown strong anti-inflammatory effect by considerably reducing paw oedema caused by formalin and carrageenan¹.

4.2 Bottle Gourd, or Lagenaria Siceraria:

Juice is traditionally used to treat obesity and metabolic issues; it is frequently consumed as a vegetable in India. Effects on metabolism (limited human data): Daily bottle gourd juice for ninety days revealed the following in a short study. Decreased total cholesterol and LDL-C.-HDL-C and fasting glucose have somewhat improved. Enhanced kidney function indicators (improved uric acid profile, lower urea).

4.3 Fenugreek or Trigonella Foenum- Graecum: Galactomannans, amino acids such 4-hydroxyisoleucine, and steroidal saponins, particularly diosgenin, are found in fenugreek seeds. Effects on metabolism: enhances insulin sensitivity and lowers fasting blood glucose. -Lowers triglycerides, LDL-C, and total cholesterol. -Viscosity and delayed absorption of carbohydrates may help somewhat with weight control.

4.4 Amla or Emblica officinalis:

Minerals, polyphenols, and vitamin C are abundant in amla. General and metabolic effects: Acts as a digestive tonic, anti-inflammatory, and antioxidant. May enhance endothelial function, glucose tolerance, and lipid profile (limited but encouraging data).

4.5 Curry leaves, Murraya koenigii:

Used extensively in traditional medicine and as a spice. Includes bioactive substances and carbazole alkaloids. Effects on metabolism: Hypoglycemic and hypolipidemic effects that were documented in early clinical and experimental research. -Used historically as a diabetic diet supplement.

4.6 Green tea, or Camellia sinensis:

In addition to caffeine and other xanthines, green tea is high in catechins, particularly epigallocatechin-3-gallate (EGCG). Effects on metabolism: High consumption of green tea is associated with a decreased incidence of T2D, CVD, and hypertension, according to observational studies. -Particularly in overweight people, clinical investigations indicate slight decreases in body weight and body fat. In certain trials, it may enhance blood pressure, glucose tolerance, and LDL-C oxidation²⁷.

4.7 Zizyphus mauritiana:

Zizyphus mauritiana leaf and fruit extracts showed strong anti-inflammatory action against paw oedema caused by carrageenan. Zizyphus jujuba contributed to the hypotensive and antinephritic effects by stimulating the release of nitric oxide. Zizyphus species contain saponins that bind bile acids and decrease the reabsorption of cholesterol³⁰.

4.8 Coriandrum Sativum:

Traditional medicine has traditionally employed Coriandrum sativum to treat metabolic and inflammatory conditions, and new research indicates that it may be useful as a nutraceutical for metabolic syndrome. In animal models, Coriandrum sativum leaf chloroform extract showed strong anti-inflammatory action, indicating a possible function for it in reducing chronic low-grade inflammation, a key pathogenic characteristic of MetS. The capacity of coriander leaves to regulate inflammatory mediators and oxidative stress linked to insulin resistance and endothelial dysfunction may be attributed to the presence of flavonoids, tannins, terpenoids, and steroids³⁶.

4.9 Ginger (Zingiber officinale):

Metabolic syndrome is a cluster of metabolic abnormalities, including obesity, insulin resistance, dyslipidemia, and hypertension, that significantly increase the risk of cardiovascular disease and type 2 diabetes. Nutraceuticals made from therapeutic plants are being investigated more and more as helpful methods of treating this illness. Gingerols, shogaols, flavonoids, and terpenoids are among the bioactive substances that contribute to the medicinal potential of ginger (Zingiber officinale), a popular dietary spice. According to studies, taking ginger supplements improves lipid profiles by raising levels of high-density lipoprotein cholesterol and lowering triglycerides, total cholesterol, and low-density lipoprotein cholesterol. By enhancing insulin sensitivity, decreasing blood sugar, and lowering oxidative stress, ginger also demonstrates antidiabetic action. Its thermogenic and appetite-modulating properties help reduce weight, which is essential for controlling the metabolic syndrome. Furthermore, the antioxidant and anti-inflammatory properties of ginger help reduce the chronic inflammation linked to obesity. All of these characteristics point to ginger as a useful nutraceutical for the supplemental treatment of metabolic syndrome³⁷.

5. Berberine:

Coptis chinensis and other plants include a plant alkaloid that is commonly used to treat T2D and dyslipidemia. Effects on metabolism: Reduces triglycerides, total cholesterol, and LDL-C. Enhances insulin sensitivity, lowers fasting glucose, and lowers hba1c (typically equivalent to metformin in several short-term studies). Enhances the adipokine profile (lower leptin, better leptin/adiponectin ratio) and reduces body weight^14,27.

6. Red Yeast Rice (RYR):

Made by fermenting rice with Monascus purpureus, it includes monacolins, particularly monacolin K, which is chemically the same as lovastatin. Effects on metabolism and blood vessels: Considerably lowers total cholesterol and LDL-C, much like low-dose statins. Reduces high-sensitivity CRP and enhances endothelial function (improved flow-mediated dilatation, reduced arterial stiffness). May enhance adipokine ratios and insulin sensitivity when used with berberine and other nutraceuticals. Secondary prevention reduces mortality and cardiovascular events, according to large Chinese studies^1,2.

7. Lantana camara Linn:

The most abundant species in this genus is Lantana camara Linn. (Verbenaceae), sometimes referred to as wild or red sage. Many Lantana species' aerial parts are widely used in traditional remedies like cancer and tumors. Fever, influenza, and stomachaches were treated with a tea made from the leaves and flowers. The plant exhibits anti-malarial, anti-bacterial, and anti-diarrheal properties in its other applications. Eddy's hot plate technique was used to screen the aqueous extract of Lantana camara for analgesic efficacy. This study was carried out to confirm the analgesic, anti-inflammatory, and anti-hemorrhoidal properties of Lantana camara aqueous extracts³⁵.

8. Carica papaya:

Rich in vitamins, minerals, dietary fiber, carotenoids, flavonoids, and phenolic compounds, carica papaya is a significant nutraceutical. By enhancing insulin sensitivity, lowering oxidative stress, and regulating lipid metabolism, these bioactive components promote metabolic health. Papaya enhances cardiovascular health, lowers LDL oxidation, and increases satiety, all of which help with weight control. Its anti-inflammatory and antioxidant qualities further lessen inflammation brought on by fat. As a result, papaya serves as a natural, multi-targeted nutraceutical that helps treat metabolic syndrome³⁸.

Evidence:

Through several processes related to blood pressure control, cholesterol improvement, and glucose regulation, herbal therapies have shown encouraging results in the management of metabolic syndrome (MetS). According to a thorough evaluation cited in the publication, herbal treatments increased HDL levels while improving metabolic markers including blood pressure, lipids, blood glucose, and waist circumference²². Plant proteins, such as soy, lupin, and pea, have been shown to improve lipid metabolism by improving hepatic LDL receptor activity and reducing LDL. Additionally, they improved diabetes indicators by lowering DPP-IV enzyme activity and promoting insulin signaling. By modifying the gut microbiota, fortifying the intestinal barrier, and increasing satiety through the production of GLP-1 and PYY hormones, probiotics, prebiotics, and synbiotics offered metabolic advantages. Through their hypoglycemic and antioxidant properties, herbal substances including curcumin, fenugreek, amla, curry leaves, and green tea improved lipid and glucose profiles, decreased inflammation, and aided in weight control. In short-term investigations, berberine and red yeast rice were found to be potent agents for controlling diabetes and dyslipidemia, on par with pharmacological therapies. All of these results demonstrate that herbal treatments are clinically relevant and economical supportive therapy methods for MetS when combined with lifestyle change^1,7.

LIMITATION:

Herbal therapies still have a number of drawbacks when it comes to managing MetS, despite promising data. The paper highlights that trials including herbs frequently have limited sample numbers, brief trial periods, and lack thorough long-term safety validation. Particularly with probiotics, where metabolic benefits were uneven and occasionally negligible for lipid improvement, many herbal treatments exhibit strain-specific or plant-specific effects, resulting in inconsistent results throughout the population. Certain herbal supplements, such as high-fiber prebiotics and legume proteins like soy and lupin, may induce gastrointestinal problems including bloating, gas, or pain. Certain populations, such as immunocompromised people using probiotics and patients exposed to high doses of vitamin D with potential for hypercalcemia, are at risk for safety issues. According to the paper, there is still little or no clinical evidence supporting the anti-obesity and lipid-regulating properties of a number of herbs, such as bottle gourd and curry leaves. Another significant issue is standardization; the active ingredients, processing, purity, and dosage forms of herbal medicines frequently vary. Additionally, using herbs with traditional MetS treatments may increase the risk of herb-drug interactions. However, the anticipated health advantages are typically not supported by thorough clinical research³⁴. Therefore, even if they are helpful, herbal treatments cannot be utilized as a stand-alone treatment; instead, more controlled clinical trials are needed to confirm their safety, effectiveness, and customized dosage^4,20.

CONCLUSION:

Due to poor eating habits, sedentary lifestyles, and rising obesity rates globally, metabolic syndrome (MetS) is becoming one of the most pressing global health issues. Central obesity, insulin resistance, dyslipidemia, hypertension, and elevated fasting glucose are all metabolic abnormalities that work in concert to greatly increase the risk of developing chronic conditions like type 2 diabetes and cardiovascular disease. The report highlights how these issues significantly impair quality of life and raise the financial strain on healthcare systems throughout the world. Glycemic management, lowering cardiovascular risk, and enhancing lipid balance have all benefited from traditional pharmaceutical methods. However, long-term medication therapy is frequently linked to unfavorable side effects, poor tolerability, and accessibility issues in many areas. The use of nutraceutical treatments and herbal medicines as supplemental therapies is therefore becoming more popular. Plant proteins, probiotics, prebiotics, synbiotics, and botanical extracts including turmeric (curcumin), fenugreek, amla, green tea, and berberine have all shown several metabolic benefits, according to the research presented in the text. Reduced triglycerides, better HDL cholesterol, greater insulin sensitivity, blood pressure management, increased satiety, and less inflammatory reactions are a few of these. Unlike other medications that concentrate on a specific component of the illness, herbal medicines' holistic approach enables them to tackle several metabolic pathways at once. These products are also widely accessible, culturally acceptable, and reasonably priced, which makes them ideal for long-term preventive usage. Their mechanisms—such as altered gut microbiota, enhanced hepatic LDL receptor expression, decreased oxidative stress and inflammatory cytokines, and improved glucose metabolism—address the underlying causes of MetS development rather than just its symptoms, indicating a very promising role for herbal-based therapeutic approaches. But the text clearly highlights important restrictions. Long-term safety, exact dosage needs, consistency in active phytochemical content, and herb-drug interaction profiles are still poorly known despite the encouraging results. Broader results cannot yet be applied uniformly because some of the research mentioned are preliminary, with small sample numbers and short clinical durations. Therefore, in situations with moderate to severe MetS, especially when problems are already apparent, herbal therapies should not take the place of conventional therapy. Therefore, an integrated, evidence-based multimodal approach is the best course of action going ahead. When medically required, herbal supplements should be used in conjunction with conventional therapy and lifestyle changes including regular exercise, weight control, and a nutritious diet. To verify safety and guarantee controlled therapeutic usage, future research must concentrate on reliable, extensive clinical trials, standardized formulations, and deeper molecular insights.

REFERENCES:

1. Sharifi-Rad E, Baradaran B, Heidari-Soureshjani M. Herbal remedies for metabolic syndrome: current perspectives. Evid Based Complement Alternat Med. 2016.https://onlinelibrary.wiley.com/doi/full/10.1155/2016/5936402

2. Yang Z, Yang J, Zhang M. Targeting metabolic syndrome with herbal pharmacology: new therapeutic insights. Front Pharmacol. 2024. Available from:https://www.frontiersin.org/articles/10.3389/fphar.2024.1366946/full

3. Park HJ, Kim HJ, Kim YC. Medicinal plants with anti-obesity effects in metabolic syndrome. Evid Based Complement Alternat Med. 2013. Available from:https://pmc.ncbi.nlm.nih.gov/articles/PMC3755736/

4. Marin-Anglada JJG, Ibáñez-Sanz JE, Roa-Dueñas LA. Nutrients and herbal bioactives in prevention of metabolic syndrome. Nutrients. 2023. Available from:https://www.mdpi.com/2072-6643/15/23/4867

5. Waghulde S, Gorde N, Kharche A, Kale M. Role of herbs in metabolic syndrome. In: Functional foods and nutraceuticals. 1st ed. Boca Raton: CRC Press; 2024. Available from:https://www.taylorfrancis.com/chapters/edit/10.1201/9781003399964-12

6. Sharma S, Khanna SN, Kumar R. Herbal remedies in metabolic syndrome: evidence and limitations. In: Natural products pharmacology. Boca Raton: CRC Press. Available from:https://books.google.co.in/books?id=GFSIEQAAQBAJ

7. Sharma P, Sharma S, Baldi A. Herbal management approaches for metabolic syndrome. 2023. Available from:https://www.sciencedirect.com/science/article/abs/pii/B978032390572500007X

8. Wiart C. Medicinal plants of Asia and metabolic syndrome. 1st ed. Boca Raton: Taylor and Francis; 2017.

9. Fang X, Chen Y, Zhang Q. Herbal bioactive constituents for metabolic syndrome therapy. Inflammopharmacology. 2025. Available from: https://link.springer.com/article/10.1007/s44187-025-00349-y

10. Li Y, Gao M, Zhou L. Pathophysiology and natural interventions for metabolic syndrome. Metabolism. 2025. Available from: https://link.springer.com/article/10.107/s44371-025-00212-0

11. Nimmerich A, Hünig T, Mitrukova O. Apolipoprotein modulation through herbal components in metabolic syndrome. Evid Based Complement Alternat Med. 2014. Available from: https://onlinelibrary.wiley.com/doi/10.1155/2014/648308

12. Sharma P, Sharma S, Baldi A. Phytoarmamentarium to manage metabolic syndrome. Boca Raton: CRC Press; 2024. Available from: https://www.taylorfrancis.com/chapters/edit/10.1201/9781003292692-3

13. Sharma P, Sharma S, Baldi A. Phytoarmamentarium to manage metabolic syndrome. Boca Raton: CRC Press; 2024. Available from:https://www.ingentaconnect.com/content/ben/emiddt/2008/00000008/00000002/art00005

14. Bhattaram VA, Graefe U, Kohlert C. Herbal medicine effects on insulin resistance and metabolic syndrome. Evid Based Complement Alternat Med. 2011. Available from:https://pmc.ncbi.nlm.nih.gov/articles/PMC3115896/

15. Talha J, Priyanka MAA. Hypertension and herbal plants. Int Res J Pharm. 2011. Available from:https://scholar.google.com/scholar_lookup?title=Hypertension%20and%20herbal%20plants

16. Chatterjee S, Khunti K, Davies MJ. Natural interventions targeting metabolic syndrome associated diabetes. Rev Endocr Metab Disord. 2014. Available from:https://link.springer.com/article/10.1007/s40618-014-0150-1

17. Miller M, Stone NJ, Ballantyne C. Phytotherapy benefits in metabolic syndrome lipid disorders. J Clin Lipidol. 2015. Available from: https://journals.sagepub.com/doi/10.1177/2156587214564188

18. Zhou SS, Li D, Zhou Y. Herbal modulation of inflammatory biomarkers in metabolic syndrome. Evid Based Complement Alternat Med. 2009. Available from:https://pmc.ncbi.nlm.nih.gov/articles/PMC2705729/

19. Banerjee S, Kar A. Role of phytochemicals in insulin resistance and metabolic syndrome. Evid Based Complement Alternat Med. 2017. Available from:https://onlinelibrary.wiley.com/doi/10.1155/2017/8943059

20. Aguilar M, Bhuket T, Liu B. Prevalence of metabolic syndrome and herbal-based therapies: updated review. Diabetes Metab Syndr Obes. 2022. Available from:https://pubmed.ncbi.nlm.nih.gov/35054972/

21. Binu P, Surya S. Antioxidant herbs against metabolic syndrome risk factors. 2020. Available from: https://europepmc.org/article/MED/33202550

22. Kakkar S, Bais S. Herbal interventions for obesity and metabolic disorders. J Ethnopharmacol. 2017. Available from:https://pubmed.ncbi.nlm.nih.gov/28639538/

23. Mirmiran P, Noori N, Azizi F. Herbal treatment strategies for metabolic syndrome components. Iran J Endocrinol Metab. 2004. Available from: https://pubmed.ncbi.nlm.nih.gov/15151470/

24. Grundy SM, Brewer HB, Cleeman JI. Definition and clinical management of metabolic syndrome: expert consensus. Lancet. 2009. Available from:https://www.thelancet.com/journals/lancet/article/PIIS0140673609617943

25. Ribeiro ALP, Lotufo PA. Pediatric metabolic syndrome and botanical therapeutics review. J Pediatr (Rio J). 2021. Available from:https://www.scielo.br/j/jped/a/bsKH4jhz6ZT3C9mykf9z8PR/

26. Rahman MM, Rahman MM, Islam MS. Herbal approaches for metabolic syndrome and associated complications. Austin J Pharmacol Ther. 2015. Available from:https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v3-id1063.pdf

27. Martirosyan DM, Lampert T. Nutraceuticals in the management and prevention of metabolic syndrome. 2014. Available from: https://www.researchgate.net/publication/275965337

28. Raj A, Kumar M, Singh S. Role of herbal drugs in metabolic syndrome management: a comprehensive review. World J Pharm Res. 2020. Available from: https://www.wisdomlib.org/science/journal/world-journal-of-pharmaceutical-research

29. Bharati D, Sonawane SA, Kanase KG, Undale VR, Abhynkar MM, Bhosale AV. Evaluation of anti-inflammatory, antipyretic and wound healing activity of Curcuma inodora. Res J Pharmacogn Phytochem. 2009. Available from:https://rjpponline.org

30. Nikhat F, Satyanarayana D, Subhramanyam EVS. Phytochemistry and pharmacology of Zizyphus mauritiana. Res J Pharmacogn Phytochem. 2009. Available from:https://rjpponline.org

31. Tripathi K. Herbs for obesity: a review. Res J Pharmacogn Phytochem. 2009. Available from:https://rjpponline.org

32. Mate GS, Umbare RP, Patil SM, Dongare SS, Naikwadi NS. Anti-inflammatory activity of Orthosiphon stamineus bark extract. Res J Pharmacogn Phytochem. 2009. Available from:https://rjpponline.org

33. Jarali Jarali AB, Radhakrishnan G. Stress, obesity and selected health problems among professionals. Asian J Nurs Educ Res. 2013. Available from: https://ajner.com

34. Singh A, Kumar R, Sharma S. Natural products and hypertension: scope and role in antihypertensive therapy. Asian J Nurs Educ Res. 2023. Available from:https://ajner.com

35. Gidwani BK, Bhargava S, Rao SP, Majoomdar A, Pawar DP, Alaspure RN. Analgesic and anti-inflammatory activity of Lantana camara. Res J Pharm Technol. 2009. Available from:https://rjptonline.org

36. Sureshkumar CA, Meera R, Devi P, Sathish M, Varadharajan R, Muthumani P. Antinociceptive and anti-inflammatory activity of Coriandrum sativum leaves. Res J Pharm Technol. 2010. Available from:https://rjptonline.org

37. Patil SB, Kothavale SD. Anti-obesity activity of Zingiber officinale. Res J Pharmacogn Phytochem. 2022. Available from: https://rjpponline.org

38. Shelke M, Tamboli A, Sonawane P, Sadaphal P, Mankar SD. Pharmacognosy and pharmacological activity of Carica papaya leaf: a review. Res J Pharmacogn Phytochem. 2021. Available from: https://rjpponline.org.

Received on 22.12.2025 Revised on 05.03.2026

Accepted on 11.04.2026 Published on 08.07.2026

Available online from July 13, 2026

Res. J. Pharmacognosy and Phytochem. 2026; 18(3):285-294.

DOI: 10.52711/0975-4385.2026.00041

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

Drug/Class	Examples	Uses	Common Side Effects
Metformin	Metformin	• Improves insulin sensitivity • Reduces hepatic glucose production	GI upset, diarrhea, metallic taste
Thiazolidinediones	Pioglitazone, Rosiglitazone	• Enhance insulin sensitivity • Reduce fasting glucose	Weight gain, edema
GLP-1 Agonists	Liraglutide, Exenatide	• Promotes weight loss • Improves glycemic control	Nausea, vomiting
DPP-4 Inhibitors	Sitagliptin, Vildagliptin	• Improve glycemic stability •Reduce post-meal glucose spikes	Headache, nasopharyngitis
SGLT2 Inhibitors	Empagliflozin, Dapagliflozin, Canagliflozin	• Reduce blood glucose • Decrease weight and BP	Genital infections, dehydration
Insulin Therapy	Glargine, Detemir, premix insulins	• Controls high fasting glucose • Used in advanced diabetes	Hypoglycemia, weight gain

Drug/Class	Examples	Uses	Side Effects
ACE Inhibitors	Enalapril, Lisinopril	• Lower BP •Reduce CV risk	Dry cough, dizziness
ARBs	Losartan, Telmisartan	• Reduce BP • Protect kidneys	Hyperkalemia, dizziness
Calcium Channel Blockers	Amlodipine, Verapamil	• Control BP •Reduce arterial stiffness	Edema, constipation
Thiazide Diuretics	Hydrochlorothiazide	• Lower BP • Reduce fluid overload	Hypokalemia, dehydration
Beta-blockers	Metoprolol, Carvedilol, Atenolol	• Lower BP •Reduce cardiac workload	Fatigue, bradycardia
Spironolactone	Spironolactone	•Treat resistant hypertension • Protect kidneys	Hyperkalemia, gynecomastia

Drug/Class	Examples	Uses	Side Effects
Statins	Atorvastatin, Rosuvastatin, Simvastatin	• Lower LDL • Reduce CV risk	Muscle pain, liver enzyme elevation
Fibrates	Fenofibrate, Gemfibrozil	• Reduce triglycerides • Improve HDL	Gallstones, muscle pain
Omega-3 Prescription	EPA/DHA formulations	• Lower triglycerides • Improve lipid profile	Fishy aftertaste, nausea
Niacin	Extended-release niacin	• Raise HDL • Lower triglycerides	Flushing, itching
PCSK9 Inhibitors	Alirocumab, Evolocumab	• Potent LDL reduction • Reduce CV events	Injection site reactions
Ezetimibe	Ezetimibe	• Lowers LDL • Used when statin response inadequate	Diarrhea, fatigue
Bile Acid Sequestrants	Cholestyramine, Colesevelam	• Lower LDL • Improve glycemic control	Constipation, bloating

Drug/Class	Examples	Uses	Side Effects
Orlistat	Orlistat	• Blocks fat absorption • Reduces body weight	Oily stools, diarrhea
Phentermine	Phentermine	• Appetite suppression • Short-term weight loss	Insomnia, increased heart rate
Phentermine–Topiramate	Combination therapy	• Strong weight reduction • Reduces appetite	Tingling, dizziness
Topiramate	Topiramate	• Weight loss support • Reduces cravings	Cognitive slowing, fatigue
Liraglutide (for obesity)	Liraglutide 3 mg	• Promotes sustained weight loss • Improves metabolic markers	Nausea, vomiting

Table No.1 Antidiabetic Drug in MetS

2. Antihypertensive Drugs:

Table No.2 Antihypertensive Drug in MetS

3. Lipid-Lowering Drugs

4. Anti-Obesity Drugs:

Table No.4 Anti-Obesity Drug in MetS

5. Antiplatelet Therapy

Table no. 5 Antiplatelet Therapy in MetS

NUTRACEUTICAL MANAGEMENT OF (METS)